“If it’s Covid, Paxlovid.”
That’s how Pfizer markets its Covid-19 antiviral, even as the full results of a study published in the New England Journal of Medicine this week adds further proof that the pill may not be as effective in vaccinated adults and those at low risk for severe symptoms.
The full study results were published in NEJM on Wednesday, though Pfizer released the initial results back in 2022. Paxlovid was granted full approval last May to treat mild-to-moderate Covid-19 in adults at high risk for developing severe Covid-19, after it was first made available under an emergency use authorization in 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.